Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-457P is a pseudogene derived from the U6 small nuclear RNA (snRNA) gene family, which is among the most conserved and essential non-coding RNAs in eukaryotes for pre-mRNA splicing[1][3]. Unlike the canonical U6 snRNA, which forms part of the spliceosome complex that removes introns from precursors to messenger RNA, pseudogenes such as RNU6-457P are generally inactive genomic elements. U6 snRNA pseudogenes typically lack function due to sequence divergence or absence of necessary regulatory sequences, and are frequent "back-up" copies scattered throughout the human genome as a byproduct of evolution[3][5]. Sequence analyses of U6 pseudogenes, including similar characterized pseudogenes, reveal high but imperfect similarity to functional U6 snRNA genes and sometimes retain features of the genuine U6 gene sequence, such as conserved 5' and 3' ends[5]. No therapeutic, diagnostic, or safety-related roles are ascribed to RNU6-457P or other U6 snRNA pseudogenes. Key Clarifications: - RNU6-457P is not a receptor, enzyme, transporter, or therapeutically actionable target. - It is a pseudogene and not expected to produce a functional RNA or protein product. - It should not be confused with the functional U6 snRNA gene, a critical catalytic RNA in the spliceosome[1][3]. If you require details about the functional U6 snRNA (not pseudogene), it is an integral, highly conserved spliceosome RNA that catalyzes the excision of introns during pre-mRNA splicing, but RNU6-457P refers specifically to a non-functional, pseudogenic copy.
None known for pseudogenes
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 457, pseudogene (RNU6-457P).